SEL 403

Drug Profile

SEL 403

Alternative Names: LMB 100/SVP Rapamycin; SEL-403; SVP Rapamycin/LMB 100

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Selecta Biosciences
  • Class Antineoplastics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Mesothelioma; Pancreatic cancer

Most Recent Events

  • 05 Oct 2017 Phase-I clinical trials in Mesothelioma in USA before October 2017 (Parenteral)
  • 05 Oct 2017 Phase-I clinical trials in Pancreatic cancer in USA before October 2017 (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top